Abbvie Inc., et al. v. Mylan Pharmaceuticals Inc., et al., C.A. No. 13-1072 – RGA, June 3, 2015

Andrews, J. Claim construction opinion regarding x disputed terms from 6 patents. Oral argument took place on May 22, 2015.

The disputed product relates to ritanovir.  The disputed claims construed are:

1. Formulated as a solid dispersion of amorphous ritonavir in a matrix including a water soluble polymer
2. Solid dispersion
3. Solid solution
4. Molecular dispersion
5. Self-emulsifying
6. Composition